Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Boost Plus Clear all
Completed Phase 3 Interventional

An Intervention to Improve Outcomes in Patients With Advanced Cancer

NCT01272024
View directory record Official record
Conditions
Cancer
Interventions
Symptom Education, Intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

NCT02654080
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 nef/tat/vif, env pDNA vaccine, rVSV HIV envC vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 23, 2026, 5:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

NCT01222572
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, NSCLC
Interventions
Stereotactic boost, Conventional RT, Etoposide, Cisplatin
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Following Pancreatic Surgery

NCT00660270
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pancreatic Surgery, Radiation therapy, Cisplatin, 5-FU, Alpha-interferon, Gemcitabine
Procedure · Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 23, 2026, 5:19 PM EDT
Recruiting Phase 2 Interventional

HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma

NCT05962242
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oropharynx
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Miami, Florida • Charlottesville, Virginia • Norfolk, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Not yet recruiting Phase 1 Interventional

Human Models of Selective Insulin Resistance: Pancreatic Clamp

NCT06558422
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

NCT01814137
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 23, 2026, 5:19 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

NCT05169970
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

NCT03589547
View directory record Official record
Conditions
Stage III Non-small-cell Lung Cancer
Interventions
Durvalumab, SBRT
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Withdrawn Not applicable Interventional

Phase I Study MR-guided SBRT to PCa

NCT03935308
View directory record Official record
Conditions
Low or Intermediate Risk Prostate Cancer
Interventions
MR guided Linear Accelerator
Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01740648
View directory record Official record
Conditions
Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
trametinib, fluorouracil, radiation therapy
Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
4
States / cities
St Louis, Missouri • Buffalo, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Phase 1 Safety Study of Two Experimental HIV Vaccines

NCT00479999
View directory record Official record
Conditions
AIDS Vaccines, HIV Infections, HIV-1
Interventions
VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional Results available

Study of Prone Accelerated Breast And Nodal IMRT

NCT02308488
View directory record Official record
Conditions
Lymphedema
Interventions
Intensity-modulated radiation therapy (IMRT)
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
36 Years to 90 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

NCT05781542
View directory record Official record
Conditions
HIV Infections
Interventions
sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571, 3M-052-AF, Alum
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional and Functional Changes in Heart Failure and COPD

NCT01787682
View directory record Official record
Conditions
Chronic Heart Failure, Chronic Obstructive Pulmonary Disorder
Interventions
BOOST High Protein
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
20 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer

NCT00084591
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 23, 2026, 5:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Arterial Stiffness in Type I Diabetes Mellitus

NCT02218268
View directory record Official record
Conditions
Arterial Stiffness in Youth With Type 1 Diabetes
Interventions
Pre-meal bolus, No meal bolus
Drug
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 23, 2026, 5:19 PM EDT
Withdrawn Phase 1 Interventional

Reirradiation With Concurrent Paclitaxel for Breast Cancer

NCT02058667
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel+Initial Radiation+Boost
Radiation
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a Supplement to Support Student Learning

NCT05528094
View directory record Official record
Conditions
Concentration Ability Impaired, Mental Fatigue
Interventions
GeniusDrops
Dietary Supplement
Lead sponsor
JoySpring
Other
Eligibility
5 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 23, 2026, 5:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

NCT03376659
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Interventions
Durvalumab, CV301, Capecitabine, Bevacizumab
Drug · Biological
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 23, 2026, 5:19 PM EDT
Active, not recruiting Phase 4 Interventional

Connective Tissue Matrix for Rotator Cuff Tendinopathy

NCT06160427
View directory record Official record
Conditions
Tendinopathy, Shoulder Pain, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis
Interventions
CTM Boost, PRP
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme

NCT00004262
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
conventional surgery, 3-dimensional conformal radiation therapy, stereotactic radiosurgery, motexafin gadolinium, magnetic resonance imaging, spectroscopy
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00004054
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Boost in Healthy Adults

NCT02586792
View directory record Official record
Conditions
Influenza
Interventions
Monovalent influenza A/H7N9 virus vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 23, 2026, 5:19 PM EDT